Pharmala Biotech (MDMA) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended May 31, 2025 was $338,122, down from $952,609 year-over-year, mainly due to fewer clinical trial shipments and loss of consulting revenue, partially offset by resumed SAP shipments in Canada.

• Net loss for the nine months ended May 31, 2025 increased to $1,814,110 from $599,241 year-over-year, driven by higher operating expenses and increased stock-based compensation.

• The company completed a $1.56M private placement in December 2024, strengthening its cash position and supporting ongoing R&D and working capital needs.

• The company continues to focus on developing and commercializing MDMA and MDXX class molecules, with a strategic shift toward intellectual property-driven business lines.

Financial highlights

• Gross profit for the nine months ended May 31, 2025 was $318,999, down from $655,647 year-over-year.

• Total expenses rose to $2,117,495 from $1,085,458 year-over-year, with significant increases in payroll, research, and stock-based compensation.

• Adjusted EBITDA loss for the nine months ended May 31, 2025 was $835,401, compared to a loss of $84,710 in the prior year period.

• Cash at May 31, 2025 was $129,861, with an additional $1.1M in short-term investments.

• No debt outstanding; all liabilities are short-term and non-interest bearing.

Outlook and guidance

• Management expects future revenue growth as clinical trial shipments resume and SAP distribution expands, but cautions that revenue recognition is dependent on regulatory approvals and customer permit timing.

• The company anticipates continued investment in R&D and intellectual property, with a focus on long-term value creation over short-term cash revenue.

• Ongoing volatility in financial markets and regulatory changes in the psychedelics sector may impact future performance.